Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.64 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10681987 | 0.97 | GABBR2 (0.62) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL6278627 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL19803214 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL20694143 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL9779274 | 0.86 | GABBR2 (0.61) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL19803301 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL7396004 | 0.86 | GABBR2 (0.61) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL20693672 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL24878661 | 0.83 | GABBR2 (0.53) | GABBR2GABBR1LMNATSHRCYP2C9 | |
| SCHEMBL21610467 | 0.83 | GABBR2 (0.53) | GABBR2GABBR1LMNATSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365575-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365575-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365575-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2852594-B1 | PYRIMIDINO[1,2-C]QUINAZOLINONE DERIVATIVES AS TYROSINE KINASES INHIBITORS | ALLERGAN INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2852594-B1 | PYRIMIDINO[1,2-C]QUINAZOLINONE DERIVATIVES AS TYROSINE KINASES INHIBITORS | ALLERGAN INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2852594-A1 | PYRIMIDINO [1, 2 -C]QUINAZOLINONE DERIVATIVES AS TYROSINE KINASES INHIBITORS | ALLERGAN, INC. (US) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013177053-A1 | PYRIMIDINO [1, 2 -C] QUINAZOLINONE DERIVATIVES AS TYROSINE KINASES INHIBITORS | ALLERGAN, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130310394-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310394-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-0226511-B1 | 5-PHENYL-1,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1989-08-02 | — | — | EP | disclosed |
| US-4774248-A | Methods of treating depression and depressive states using 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1988-09-27 | — | — | US | disclosed |
| EP-0226511-A1 | 5-Phenyl-1,4,5,6-tetrahydropyrimidine derivatives, preparation process and medicinal use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-06-24 | — | — | EP | disclosed |
| EP-0024776-B1 | 4-PHENYL AND 5-PHENYL-1,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES, AND PROCESS FOR PREPARING SAID DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4322421-A | 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydro-pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4261995-A | DISORDERS OF CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR SYSTEM; HYPOTENSIVE | SYNTEX (U.S.A.) INC. (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0024776-A1 | 4-Phenyl and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives, pharmaceutical compositions containing said derivatives, and process for preparing said derivatives | SYNTEX (U.S.A.) INC. (US) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310394-A1 | KINASE INHIBITORS | CSNK1A1, MAPK1, MAP3K1 | GABBR2 2377/4885GABBR1 2348/4885LMNA 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.